Breaks Categories: News

TuesdayJan 14, 2025 10:34 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, has received a U.S. patent for methods using buntanetap to treat and prevent acute brain and nerve injuries. The patent, issued on Jan. 2, 2025 (US-2025-0000846-A1), covers buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes in conditions such as stroke, ischemia, traumatic brain injury, and micro infarcts. Already patented in the EU, Japan, and globally, this approval enhances Annovis’ intellectual property portfolio. CEO Maria Maccecchini, Ph.D., emphasized buntanetap's potential to protect and restore neuronal health, expanding its applications beyond Alzheimer’s and Parkinson’s disease. To view the full press release,…

Continue Reading

TuesdayJan 14, 2025 8:45 am

BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company focused on neurological disorders, has received a Notification to Grant Patent Right for its Chinese invention patent application (No: 2020800553323). The patent covers compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, including autism, using a novel intranasal suramin formulation. CEO Howard Weisman highlighted this as a historic milestone, marking the first intellectual property protection for suramin in over a century. PaxMedica plans to pursue similar protections in additional jurisdictions, including the United States. To view the full press release, visit https://ibn.fm/DW1iE About PaxMedica Inc. PaxMedica is a forward-looking,…

Continue Reading

TuesdayJan 14, 2025 7:35 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites," has been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting, April 25-30, 2025, in Chicago. The presentation will highlight Calidi’s proprietary RTNova systemic platform, which leverages a novel vaccinia virus strain enveloped with a human cell membrane to overcome immune system elimination, enabling targeted delivery to multiple metastatic tumor sites. This innovative approach aims to address treatment challenges in advanced metastatic cancers, such as lung cancer, where…

Continue Reading

MondayJan 13, 2025 7:30 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close on or around Jan. 10, 2025, subject to customary conditions. Proceeds will support working capital and general corporate purposes. The shares are offered under an effective Form S-3 registration statement, with a final prospectus available on the SEC’s website or through Ladenburg Thalmann. To view…

Continue Reading

FridayJan 10, 2025 9:41 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering's size and terms depend on market conditions and are yet to be finalized. Proceeds will support working capital and general corporate purposes. The securities will be offered under an effective shelf registration statement filed with the SEC, and interested parties can access the preliminary prospectus and accompanying documents via the SEC website or through Ladenburg Thalmann's Prospectus…

Continue Reading

TuesdayJan 07, 2025 1:10 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials that are now integrated into a single 6/18-month trial under the…

Continue Reading

MondayJan 06, 2025 8:50 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences

Scinai Immunotherapeutics (NASDAQ: SCNI) a biopharmaceutical company focused on inflammation and immunology products and CDMO services, announced CEO Amir Reichman and Chairman Mark Germain will participate in several high-profile events in January 2025. They will attend the IATI Mini Mixiii Conference in Miami on January 9, followed by the JP Morgan HealthCare Conference and SIC Biotech Symposium in San Francisco from January 13-15. The executives plan to meet with investors, potential pharmaceutical partners, and prospective CDMO clients to advance collaborations and highlight Scinai's innovative NanoAbs and biologics services. To view the full press release, visit https://ibn.fm/fkDUg About Scinai Immunotherapeutics Ltd.…

Continue Reading

MondayDec 23, 2024 10:12 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference

HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025, in San Francisco. CEO Robert Eno and CFO Timothy Cruickshank will meet with investors and potential partners to discuss the recently FDA-cleared HeartBeam system, the first cable-free, credit card-sized ECG device designed for comprehensive arrhythmia assessment. Combining its patented high-fidelity ECG technology with AI-driven analysis, HeartBeam aims to provide a longitudinal view of cardiac health, transforming cardiovascular diagnostics and predictive care for millions of patients worldwide. To view the full press release, visit https://ibn.fm/hv8sI…

Continue Reading

ThursdayDec 19, 2024 10:33 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility to Advance Neurodegenerative Disease Treatments

Clene (NASDAQ: CLNN) has announced a $10 million debt facility with three affiliated entities, set to close by December 20, 2024. The 18-month secured, partially convertible note carries a 12% fixed interest rate, with an interest-only period for the first year. Sixty-five percent of the note is convertible into common stock at $5.67 per share, a 130% premium over the stock’s signing day closing price. Proceeds will support Clene’s development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval. The company also aims to repay its prior $7.9 million Loan Agreement with Avenue Venture…

Continue Reading

WednesdayDec 18, 2024 3:02 pm

BioMedNewsBreaks — Lantern Pharma Inc. (LTRN) Expands HARMONIC™ Trial to Asia with First Patient Dosed in Taiwan

Lantern Pharma (LTRN)  has enrolled and dosed its first patient in Taiwan for the Phase 2 HARMONIC™ trial evaluating LP-300 in never-smokers with non-small cell lung cancer (“NSCLC”) who have relapsed after tyrosine kinase inhibitor (“TKI”) treatment. This expansion into Asia addresses the region's higher prevalence of never-smoker NSCLC cases, with Taiwan being a key area as over half of lung cancer diagnoses there occur in never-smokers. The trial, conducted across sites in the U.S., Japan, and Taiwan, aims to enroll 90 patients to assess progression-free survival (“PFS”) and overall survival (“OS”) outcomes. Lantern highlighted promising preliminary results, including an…

Continue Reading